Crown Bioscience Launches Life Science Product Catalog

Share Article

Tools to support preclinical research, drug development and validation

News Image
Crown Bioscience launches a new Life Science division specializing in in vivo and in vitro research reagents for preclinical research.

Crown Bioscience, Inc., a leading global drug discovery and development service company, has launched a new Life Science division specializing in in vivo and in vitro research reagents for preclinical research.

The first products released include in vivo grade human and mouse monoclonal antibody isotype controls, and soon to be released in vivo grade monoclonal antibodies against PD-L1 and PD-1. The company will continue to expand their life science portfolio with additional antibody products as well as unique pathway reporter, neoantigen and recombinant cell lines.

“We are excited to be offering our first reagent products to support preclinical research, drug development, and product validation,” says Dr. Jean Pierre Wery, President of Crown Bioscience. “Many of these products were initially developed for our own internal needs to support some of the clinical development work we have been doing for our existing customers. Clearly we saw a need for these products and felt that making these reagents readily available would be of benefit to many of our existing customers, as well as potential customers,” says Dr. Wery.

The first reagent products are ready to ship to customers around the world. More information about Crown Bioscience’s new line of reagent products can be found at http://www.crownbio.com/products.

###

About Crown Bioscience Inc.

Founded in 2006, Crown Bioscience is a premier drug discovery and development service company providing cutting-edge translational platforms and cost effective drug discovery solutions for its biotech and pharmaceutical partners in dedicated therapeutic areas: Oncology and Metabolic Disease. Our proprietary HuPrime®, HuKemia®, HuBase™, HuMark™, HuTrial™ and HuSignature™ platforms enable unique lead optimization and translational strategies to deliver superior clinical candidates. Headquartered in Santa Clara, California, Crown Bioscience has operations in China (Beijing and Jiangsu Taicang), United Kingdom (Nottingham) and the USA (NC) with business offices in Boston, Princeton, RTP, Phoenix, Milan and Shanghai. For more information, please visit http://www.crownbio.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Lauren Roper
Crown Bioscience
+1 855-827-6968 Ext: 704
Email >
Visit website